Second Sight confirms positive Long-Term Results of the Argus II Retinal Prosthesis System Print E-mail
By William Kent   
Tuesday, 23 June 2015 14:51

Manufacturer of virtual prosthetics, Second Sight Medical Products, which provides useful vision for blind patients, has confirmed three year results post-implant of the Argus II Retinal Prosthesis System from multi-center clinical trial.

 

This paper has title of “Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind”, and accentuates on 30 subjects implanted with Argus II at ten centres in US as well as Europe.

Three types of visual function tests were done utilising computer-run assessments. Also, two types of real-world orientation and mobility (O&M) tests were done which is done for locating and touching a door.

Of 30 subjects tested, 29 remained implanted with functioning Argus II systems at three years post-implant. About 89 percent of subjects performed statistically better with the system implanted.

Dr. Allen C. Ho, MD FACS, Director of Retina Research, Wills Eye Hospital and Professor of Ophthalmology, Thomas Jefferson University, stated that data from the study is remarkable and can be life changing for many individuals.

President and CEO of Second Sight Mr Greenberg opined that the firm is thrilled on witnessing positive results from the study which shows support as well as benefit of Argus II. Greenberg further opined that the trial shows long-term reliability as well as benefit to the users.

Dr. Greenberg added that it is the starting and that firm is making improvements in image quality as well as resolution for the Argus II. He further stated that the present development efforts toward Orion I Cortical Visual Prosthesis would be offering solutions for people with blindness.

The Argus II System is the only retinal implant to get both approvals. Even though there are many research efforts in retinal prostheses world over, none have shown reliability as well as effectiveness of a device in long-term and controlled clinical trial having 30 subjects.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter